itanoxone: RN from 9th CI Form Index; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 42667 |
| CHEMBL ID | 2104844 |
| SCHEMBL ID | 2112233 |
| MeSH ID | M0082109 |
| Synonym |
|---|
| itanoxone [inn] |
| 2-(p-(o-chlorophenyl)phenacyl)acrylic acid |
| 2'-chloro-alpha-methylene-gamma-oxo-(1,1'-biphenyl)-4-butanoic acid |
| brn 2138480 |
| itanoxono [inn-spanish] |
| f 1379 |
| itanoxonum [inn-latin] |
| (1,1'-biphenyl)-4-butanoic acid, 2'-chloro-alpha-methylene-gamma-oxo- |
| 2-methylene-4-oxo-4-(4'-ortho-chlorophenylphenyl)butyric acid |
| acide (chloro-2' biphenylyl-4)-4 methylene-2 oxo-4 butyrique [french] |
| itanoxone |
| 4-[4-(2-chlorophenyl)phenyl]-2-methylidene-4-oxobutanoic acid |
| 1i364q5595 , |
| unii-1i364q5595 |
| itanoxono |
| acide (chloro-2' biphenylyl-4)-4 methylene-2 oxo-4 butyrique |
| 58182-63-1 |
| itanoxonum |
| CHEMBL2104844 |
| SCHEMBL2112233 |
| DTXSID40206908 |
| Q27252443 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pretreatment with itanoxone partially prevented the inhibitory effect of aspirin on both platelet and vascular prostaglandin synthesis." | ( Differential effects of itanoxone--a new hypolipidemic and hypouricemic drug--on platelet and vascular prostaglandin generation in rats. de Gaetano, G; Delhon, A; Lauressergues, H; Livio, M; Maynadier, B; Palmier, C; Villa, S, 1981) | 0.89 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic and metabolic study of itanoxone and clofibric acid in the crab shows a difference between the two drugs." | ( Pharmacokinetic and metabolic study of itanoxone in the crab Pachygrapsus marmoratus (Decapoda, Brachyura): comparative study with clofibric acid. Chanal, JL; Delhon, A; Lautier, J, 1986) | 0.8 |
| " Profound changes in pharmacokinetic parameters, most specifically in the distribution, elimination, and metabolic pathways, were induced by substitution in the aromatic nucleus or changes in saturation of the aliphatic chain." | ( Comparison of the metabolism and pharmacokinetics of metbufen and itanoxone and their analogues in rats. Audran, M; Bret, MC; Chanal, JL; Cousse, H; Fauran, F; Rieu, JP, 1988) | 0.51 |
| " The mean elimination half-life was 19." | ( Pharmacokinetics, metabolism and elimination of itanoxone in humans. Crawley, FE; Donath, A; Hyacinthe, R; Poitou, P, ) | 0.39 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||